Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone all individually reduce cardiovascular, kidney, and mortality outcomes in patients with type 2 diabetes and albumin...

Full description

Saved in:

Bibliographic Details
Published in:	Circulation (New York, N.Y.) Vol. 149; no. 6; p. 450
Main Authors:	Neuen, Brendon L, Heerspink, Hiddo J L, Vart, Priya, Claggett, Brian L, Fletcher, Robert A, Arnott, Clare, de Oliveira Costa, Julianna, Falster, Michael O, Pearson, Sallie-Anne, Mahaffey, Kenneth W, Neal, Bruce, Agarwal, Rajiv, Bakris, George, Perkovic, Vlado, Solomon, Scott D, Vaduganathan, Muthiah
Format:	Journal Article
Language:	English
Published:	United States 06.02.2024
Subjects:	Albuminuria - drug therapy Canagliflozin - therapeutic use Cardiovascular Diseases Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Diabetic Nephropathies - etiology Glucagon-Like Peptide 1 - pharmacology Glucagon-Like Peptide 1 - therapeutic use Glucagon-Like Peptide-1 Receptor Agonists Humans Kidney Middle Aged Renal Insufficiency, Chronic Sodium-Glucose Transporter 2 Inhibitors - adverse effects mortality heart failure diabetes mellitus, type 2 renal insufficiency, chronic treatment outcome
ISSN:	1524-4539, 1524-4539
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!